Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial
Hedy L. Kindler, Silvia Novello, Alessandra Bearz, Giovanni Luca Ceresoli, Joachim G.J.V. Aerts, James Spicer, Paul Taylor, Kristiaan Nackaerts, Alastair Greystoke, Ross Jennens, Luana Calabrò, Jacobus A. Burgers, Armando Santoro, S. Cedrés, Piotr Serwatowski, Santiago Ponce, Jan P. van Meerbeeck, Anna K. Nowak, George R. Blumenschein, Jonathan Siegel, Linda Kasten, Karl Köchert, Annette O. Walter, Barrett H. Childs, Cem Elbi, Raffit Hassan, Dean A. Fennell
Topics & Concepts
MedicineMesothelinPemetrexedVinorelbineBevacizumabInternal medicineMesotheliomaOncologyClinical endpointResponse Evaluation Criteria in Solid TumorsPopulationChemotherapyPhases of clinical researchSurgeryClinical trialCancerPathologyEnvironmental healthCisplatinOccupational and environmental lung diseasesPleural and Pulmonary DiseasesMyasthenia Gravis and Thymoma